Abstract: A yard waste bag device is provided having a rectangularly tubular structure with rounded lower edges, adapted to maintain a bag opening while loading contents therein. The device comprises two open ends, a hollow interior and rotating corners adapted to allow a condensed, folded configuration for storage. A user may slide this assisting device into a yard waste bag in order to maintain the bag opening, whether in a vertical or horizontal position. Once the yard waste bag is full, the assisting device may be removed and stored. There is a designated marker within the device to identify the fill mark for the bag to prevent overfilling. A handle may be provided in the top edges of the device to facilitate removal of the device once the bag has been filled. The lower edges of the device are rounded to facilitate smooth entry into a yard waste bag.

Abstract: Methods of treating, preventing or managing triple negative breast cancer (TNBC) or clear cell renal cell carcinoma (ccRCC) are disclosed. The methods encompass the administration of an HDAC inhibitor romidepsin in combination with a cytidine analog. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods provided herein are also disclosed.

Abstract: Gene expression profiling and hierarchical clustering analysis readily identify differential gene expressions in normal renal epithelial cells and renal cell carcinomas. Genes identified by this analysis would be useful for diagnosis, prognosis and development of targeted therapy for the prevention and treatment of conventional renal cell carcinoma.

Abstract: A yard waste bag device is provided having a rectangularly tubular structure with rounded lower edges, adapted to maintain a bag opening while loading contents therein. The device comprises two open ends, a hollow interior and rotating corners adapted to allow a condensed, folded configuration for storage. A user may slide this assisting device into a yard waste bag in order to maintain the bag opening, whether in a vertical or horizontal position. Once the yard waste bag is full, the assisting device may be removed and stored. There is a designated marker within the device to identify the fill mark for the bag to prevent overfilling. A handle may be provided in the top edges of the device to facilitate removal of the device once the bag has been filled. The lower edges of the device are rounded to facilitate smooth entry into a yard waste bag.

Abstract: Gene expression profiling and hierarchical clustering analysis readily identify differential gene expressions in normal renal epithelial cells and renal cell carcinomas. Genes identified by this analysis would be useful for diagnosis, prognosis and development of targeted therapy for the prevention and treatment of conventional renal cell carcinoma.

Abstract: The present invention provides methods of preventing or reducing oxytocin-mediated action by using a thiazolidinedione, such as troglitazone, or thiazolidinedione-like compounds. These methods describe the employment of these compounds alone or in combination with at least one other agent, such as a tocolytic agent. This offers a novel therapeutic regimen for the treatment of oxytocin-mediated actions, for example induction of uterine contractions, prostaglandin release, and milk letdown. Accordingly, conditions such as preterm labor and labor prior to Caesarian delivery can be treated by these methods.

Abstract: The present invention concerns the use of transdifferentiated cells to treat pancreatic diseases. More particularly, it provides methods for the culture and transdifferentiation of human cord blood, cells into insulin-secreting cells. It also concerns the endocrine hormones, such as insulin, produced by such cultures, and the use of the transdifferentiated cells in the treatment of diabetes.

Abstract: This document provides methods and materials related to assessing the effectiveness of cancer treatments in mammals. For example, this document provides nucleic acids and polypeptides that can be analyzed to assess the effectiveness of a treatment (e.g., treatment with a PPAR? agonist) for cancer (e.g., anaplastic thyroid carcinoma) in mammals.

Abstract: The proliferation of uterine fibroid leiomyoma cells is inhibited by certain Fibroid Cell Growth Inhibitor (FGI) agents. Pharmacological doses of FGI agents can be made high enough to not only inhibit proliferation, but to cause cell death. Non-invasive or minimally invasive, non-systemic delivery methods deliver the FGI agent to the target fibroid leiomyoma cell population, thereby avoiding the disadvantages and side effects of surgical and systemic hormonal therapy interventions for treatment of uterine fibroids. The FGI agents are substrates normally present and well tolerated in humans. The efficacy of the FGI agents relates to their ability to moderate Protein Kinase C and Mitogen Activated Protein Kinase pathways. Specific FGI agents shown to be useful to inhibit growth of uterine fibroid cells include: ?-tocopherol, ?-tocopherol succinate, and troglitazone. Delivery of FGI agents to the target uterine fibroid cells may be accomplished by intra-vaginal and in situ injection techniques.

Abstract: The present invention includes the selection and isolation of thioaptamers that target the signaling protein TGF-?1, compositions of such thioaptamers and the use of such thioaptamers to either block or enhance signal transduction of the TGF-?1 protein and thus function as, e.g., immunomodulatory agents. Thioaptamers may also be targeted alone or in combination with other thioaptamers against the ligand, the receptors, the ligand trap protein(s) and/or the co-receptors to modulate TGF-? signaling pathway.

Abstract: Gene expression profiling and hierarchical clustering analysis readily identify differential gene expressions in normal renal epithelial cells and renal cell carcinomas. Genes identified by this analysis would be useful for diagnosis, prognosis and development of targeted therapy for the prevention and treatment of conventional renal cell carcinoma.

Abstract: The present inventions relate to the use of thiazolidinedione compounds, including troglitazone, either alone or in combination with other cancer treatments, for the treatment of cancer. These combination therapies employ thiazolidinedione compounds in conjunction with anticancer treatments, such as chemotherapeutic agents.

Abstract: The present invention details the use of oxytocin or oxytocin analogs as a novel therapeutic regimen for the treatment of various bone diseases and for assisting in bone remodeling. Oxytocin and oxytocin analogs can be administered alone or in combination with other agents used to treat bone diseases or aid in bone remodeling. In addition, agents which induce endogenous oxytocin release are also contemplated in the present invention for treatment of bone diseases and for assisting in bone remodeling. Diseases and conditions that are contemplated to benefit from the present invention include osteoporosis, osteopenias, bone fractures and bone remodeling surgery.